Weight-Loss Drug Trials Rarely Register Reproductive Outcomes
Only 2 of 230 weight-loss drug trials registered reproductive outcomes, revealing an evidence gap—not proof of harm to fertility.
Summary
Major trials of weight-loss medications rarely register measures of reproductive function, according to a review of ClinicalTrials.gov records. Researchers examined 230 randomized trials involving adults and found that only two registered any reproductive outcome. Both involved women with polycystic ovary syndrome. None of the 228 trials enrolling men registered a named male reproductive hormone or semen measure. In contrast, 33 trials registered body-composition outcomes. The findings highlight a gap in publicly discoverable evidence, not proof that the medications harm fertility or that researchers never collected reproductive data. For patients and clinicians, the takeaway is to acknowledge uncertainty when discussing reproductive goals alongside weight management. Trial sponsors could make existing assessments easier to find by registering them. This summary is based on the abstract only.
Detailed Summary
Weight-loss medications are widely used to improve metabolic health, but their effects on reproductive function also matter to women and men. A new study examined whether major drug trials publicly registered reproductive assessments, highlighting how difficult it may be to find evidence about fertility and related hormones alongside better-documented weight outcomes.
Researchers reviewed ClinicalTrials.gov records as registered on August 31, 2026. They included 230 randomized, controlled trials of weight-management medications in adults, covering 91 drug development programs and 3,711 registered outcome measures. Eligible studies were Phase 3 or Phase 2/3, with weight or body mass index listed as a primary outcome.
Only two trials, or 0.87%, registered any reproductive outcome. Both involved women with polycystic ovary syndrome and had non-industry sponsors. None of the 228 trials enrolling men registered a named male reproductive hormone or semen measure. Among 152 trials involving GLP-1-based medications, just two registered reproductive outcomes. By comparison, 33 trials registered body-composition measures; 31 of those registered no reproductive measure.
These findings identify a transparency gap, not evidence that weight-loss medications damage fertility or disrupt hormones. For clinicians and patients, the practical message is to recognize the limits of publicly discoverable evidence when discussing reproductive goals during weight management. Trial sponsors could improve transparency by registering reproductive assessments whenever they collect them. The study does not establish whether any particular medication improves or worsens reproductive function.
This was a cross-sectional analysis of registry entries, not an assessment of patient outcomes or complete trial reports. Missing registration does not prove that researchers omitted reproductive testing. Some additional analyses were conducted after the main analysis was planned, and results depend on the study's definitions and eligibility rules. This summary is based on the abstract only; the full paper was unavailable for evaluation. No treatment changes follow from these findings alone.
Key Findings
- Only 2 of 230 trials registered reproductive outcomes: 0.87%, with a 95% confidence interval of 0.11%–3.11%.
- Both trials registering reproductive outcomes involved women with polycystic ovary syndrome and had non-industry sponsors.
- None of 228 trials enrolling men registered a named male gonadal hormone or semen measure.
- Among 152 trials of GLP-1-based medications, two registered reproductive outcomes; 31 of 33 body-composition trials registered none.
- Missing registry outcomes indicate limited discoverability, not demonstrated reproductive harm or proof that testing never occurred.
Methodology
This cross-sectional meta-research study classified registered outcomes in ClinicalTrials.gov records for 230 randomized, controlled adult Phase 3 or Phase 2/3 weight-management medication trials. Researchers used a published classification dictionary, exact confidence intervals, and paired counts; program-level, mechanism-specific, and age-relaxed analyses were post hoc.
Study Limitations
This summary is based on the abstract only, without access to the full paper. Registry entries cannot establish whether reproductive assessments were actually performed, published elsewhere, or associated with benefit or harm. Findings depend on eligibility criteria and outcome classification, and several secondary analyses were post hoc.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: